logo
Rhythm Pharmaceuticals price target raised to $102 from $88 at Leerink

Rhythm Pharmaceuticals price target raised to $102 from $88 at Leerink

Leerink raised the firm's price target on Rhythm Pharmaceuticals (RYTM) to $102 from $88 and keeps an Outperform rating on the shares. The firm is updating its estimates for the company following this morning's disclosure of bivamelagon Phase 2 data in acquired hypothalamic obesity study that it sees as 'close to a best-case scenario', the analyst tells investors in a research note. Investor feedback has been highly positive on the efficacy, with minimal concerns on safety, the firm added.
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Wall Street Sees Over 30% Upside in MSTR Stock Ahead of Q2 Results
Wall Street Sees Over 30% Upside in MSTR Stock Ahead of Q2 Results

Business Insider

time39 minutes ago

  • Business Insider

Wall Street Sees Over 30% Upside in MSTR Stock Ahead of Q2 Results

Strategy (MSTR), the largest corporate owner of Bitcoin in the world, is scheduled to announce its results for the second quarter of 2025 on Thursday, July 31. MSTR stock has rallied 40% year-to-date and over 140% over the past year, mainly due to its large Bitcoin holdings and the rise in crypto prices. Growing interest in Bitcoin ETFs and steady gains in its software business have also helped lift the stock. Ahead of the results, Wall Street remains upbeat on MSTR stock, projecting over 30% upside from current levels. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. What to Watch on July 31 The company, earlier known as MicroStrategy, is expected to report a narrower loss per share of $0.10 for Q2 2025 compared to $0.57 per share in the prior-year quarter. Analysts expect MSTR to report Q2 revenue of $13.65 million, reflecting a year-over-year growth of 2%. Investors will be watching for management's comments on its Bitcoin strategy, along with any updates on the company's software business. Top Analyst's Views about MSTR Stock Ahead of Q2 results, Top analyst Lance Vitanza of TD Cowen raised his price target on MSTR stock to a Street-high of $680, up from $590, and kept a Buy rating. Vitanza believes Bitcoin could hit $155,000 by December, which could push MSTR stock much higher, since it closely follows Bitcoin's price. Looking ahead, the analyst expects MSTR to keep buying more Bitcoin using funds raised through the capital markets. Is MicroStrategy a Good Stock to Buy? Strategy (formerly known as MicroStrategy) continues to win over analysts. According to TipRanks, the stock currently holds a Strong Buy rating based on 12 analyst reviews: 11 Buys, zero Holds, and just one lonely Sell. The average 12-month MSTR price target is $541, implying 33.29% upside potential.

‘It's an Easy Call,' Says Top Investor About Palantir Stock
‘It's an Easy Call,' Says Top Investor About Palantir Stock

Business Insider

timean hour ago

  • Business Insider

‘It's an Easy Call,' Says Top Investor About Palantir Stock

Palantir (NASDAQ:PLTR) stock, like any investment, requires weighing the potential rewards against the risks. While the company continues to perform exceptionally well, the primary – and arguably only – factor giving investors pause is its elevated share price. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. That concern hasn't slowed the stock's momentum. Palantir shares have surged by over 500% in the past 12 months, and late last week, the company reached yet another record high. Its valuation multiples now tower over sector medians by thousands of percentage points, raising questions about whether the fundamentals can keep pace with investor enthusiasm. Next week's Q2 earnings report, scheduled for August 4th, could provide a timely reality check. It offers a critical opportunity for the company to justify its lofty valuation – or fall short of the market's high expectations. Top investor Rick Orford, who's ranked among the top 1% of stock pickers on TipRanks, is leaning toward the former scenario. He anticipates another upswing in PLTR shares following the earnings release, making it an easy call given the current trajectory. 'Should Palantir hit its Q2'25 targets – and with how the wind is blowing, that could happen – I think Palantir shareholders will be pleased. His optimism is rooted in both historical performance and Palantir's current momentum. Historically, the stock has swung an average of 17.5% following earnings – a double-edged sword, but one that Orford believes will cut favorably this time. Central to that belief is the company's AI Platform (AIP), which helped drive a 39% year-over-year revenue increase last quarter. That growth has been especially notable in Palantir's U.S. commercial segment, where AIP adoption led to a 71% revenue spike in Q1. According to Orford, this surge reflects a broader trend: companies across the country are scrambling to implement AI but often lack the in-house expertise. Palantir's AIP provides them with a ready-made solution. 'American enterprises are most likely desperate to implement AI solutions, but not all of them have the technical expertise to do so. With AIP, these enterprises get what they need to implement custom AI into their operations,' the investor explains. Orford also sees Palantir's government work as a key stabilizing force. Its deep ties to the U.S. defense sector – with multi-year, high-margin contracts – offer a steady revenue stream that cushions any slowdown in the private market. 'Palantir checks all the boxes of an exciting, growing company that's at the intersection of two major trends: enterprise AI adoption and national defense modernization,' the investor sums up. 'Analysts say Hold, but history says otherwise.' Unsurprisingly, Orford gives PLTR shares a Strong Buy rating. (To watch Orford's track record, click here) The analyst consensus on PLTR is indeed a Hold, based on 10 Hold ratings, 4 Buys, and 3 Sells. The average 12-month price target stands at $109.50, implying a 31% downside from current levels. (See PLTR stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.

Seaport Global Keeps Their Buy Rating on Badger Meter (BMI)
Seaport Global Keeps Their Buy Rating on Badger Meter (BMI)

Business Insider

time3 hours ago

  • Business Insider

Seaport Global Keeps Their Buy Rating on Badger Meter (BMI)

In a report released today, Scott Graham from Seaport Global reiterated a Buy rating on Badger Meter, with a price target of $265.00. The company's shares closed last Friday at $193.01. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Graham covers the Industrials sector, focusing on stocks such as nVent Electric, Ametek, and Hubbell B. According to TipRanks, Graham has an average return of 11.4% and a 61.88% success rate on recommended stocks. In addition to Seaport Global, Badger Meter also received a Buy from Maxim Group's Tate Sullivan in a report issued on July 24. However, on July 23, Stifel Nicolaus maintained a Hold rating on Badger Meter (NYSE: BMI).

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store